Search Results - "FOLIN, Annika"

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
  2. 2
  3. 3

    Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling by Maruwge, Wessen, D'Arcy, Pádraig, Folin, Annika, Brnjic, Slavica, Wejde, Johan, Davis, Anthony, Erlandsson, Fredrik, Bergh, Jonas, Brodin, Bertha

    Published in OncoTargets and therapy (01-11-2008)
    “…The growth of many soft tissue sarcomas is dependent on aberrant growth factor signaling, which promotes their proliferation and motility. With this in mind,…”
    Get full text
    Journal Article
  4. 4

    EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma by Tzogani, Kyriaki, van Hennik, Paula, Walsh, Ita, De Graeff, Pieter, Folin, Annika, Sjöberg, Jan, Salmonson, Tomas, Bergh, Jonas, Laane, Edward, Ludwig, Heinz, Gisselbrecht, Christian, Pignatti, Francesco

    Published in The oncologist (Dayton, Ohio) (01-05-2018)
    “…On August 28, 2015, a marketing authorization valid through the European Union was issued for panobinostat, in combination with bortezomib and dexamethasone,…”
    Get full text
    Journal Article
  5. 5
  6. 6

    A retrospective safety analysis of adult patients treated with high-dose methotrexate for osteosarcoma in Stockholm, Sweden by Alm, Daniel, Linder Stragliotto, Christina, Folin, Annika, Bergh, Jonas, Foukakis, Theodoros

    Published in Journal of clinical oncology (20-05-2012)
    “…Abstract only 10083 Background: Patients with osteosarcoma are routinely treated with pre- and post-operative chemotherapy that includes high-dose…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment by Hast, Robert, Wallvik, Jonas, Folin, Annika, Bernell, Per, Stenke, Leif

    Published in Leukemia research (2001)
    “…The outcome of continued EPO therapy was studied in 18 responding MDS patients. The EPO dose was reduced in a stepwise fashion to find the lowest possible…”
    Get full text
    Journal Article
  9. 9

    Comparison between histologic type, estrogen receptor, and nuclear DNA content in mammary carcinoma by Erhardt, K, Auer, G, Folin, A, Silfverswärd, C, Skoog, L

    Published in American journal of clinical oncology (01-02-1986)
    “…Histological specimens from 80 invasive breast carcinomas comprising typical cases of 16 ductal, nine papillary, 14 comedo, 13 colloid (mucous), 15 lobular,…”
    Get more information
    Journal Article
  10. 10

    Prognostic significance of nuclear DNA analysis in histological sections in mammary carcinoma by Erhardt, K, Auer, G, Fallenius, A, Folin, A, Forsslund, G, Silfverswärd, C, Zetterberg, A

    Published in American journal of clinical oncology (01-04-1986)
    “…The nuclear DNA content in tumor cells from invasive ductal breast carcinomas was analyzed in 26 patients who survived more than 10 years and in 23 patients…”
    Get more information
    Journal Article